BACKGROUND: The epidemiological evidence on possible relationships between coffee consumption and prostate cancer (PCa) risk by subtype of the disease (localized, advanced) and fatal PCa risk is limited. MATERIALS AND METHODS: A population-based cohort of 44 613 Swedish men aged 45-79 years was followed up from January 1998 through December 2010 for incidence of localized (n = 2368), advanced (n = 918) and fatal (n = 515) PCa. We assessed the associations between coffee consumption and localized, advanced and fatal PCa risk using competing-risk regressions. We examined possible effect modification by body mass index (BMI). RESULTS: For localized PCa, each one cup increase in daily coffee consumption was associated with a 3% reduced risk [sub-hazard ratio (SHR) = 0.97, 95% confidence interval (CI) = 0.95-0.99]. For advanced and fatal PCa, we found a non-significant inverse association; each one cup increase was associated with a 2% reduced risk of advanced [SHR (95% CI) = 0.98 (0.95-1.02)] and fatal PCa [SHR (95% CI) = 0.98 (0.93-1.03)]. We observed evidence of effect modification by BMI for localized PCa (Pinteraction = 0.03); the inverse association was stronger among overweight and obese men (BMI ≥ 25 kg/m(2)) compared with normal-weight men (BMI < 25 kg/m(2)). CONCLUSIONS: We observed a clear inverse association between coffee consumption and risk of localized PCa, especially among overweight and obese men.
BACKGROUND: The epidemiological evidence on possible relationships between coffee consumption and prostate cancer (PCa) risk by subtype of the disease (localized, advanced) and fatal PCa risk is limited. MATERIALS AND METHODS: A population-based cohort of 44 613 Swedish men aged 45-79 years was followed up from January 1998 through December 2010 for incidence of localized (n = 2368), advanced (n = 918) and fatal (n = 515) PCa. We assessed the associations between coffee consumption and localized, advanced and fatal PCa risk using competing-risk regressions. We examined possible effect modification by body mass index (BMI). RESULTS: For localized PCa, each one cup increase in daily coffee consumption was associated with a 3% reduced risk [sub-hazard ratio (SHR) = 0.97, 95% confidence interval (CI) = 0.95-0.99]. For advanced and fatal PCa, we found a non-significant inverse association; each one cup increase was associated with a 2% reduced risk of advanced [SHR (95% CI) = 0.98 (0.95-1.02)] and fatal PCa [SHR (95% CI) = 0.98 (0.93-1.03)]. We observed evidence of effect modification by BMI for localized PCa (Pinteraction = 0.03); the inverse association was stronger among overweight and obesemen (BMI ≥ 25 kg/m(2)) compared with normal-weight men (BMI < 25 kg/m(2)). CONCLUSIONS: We observed a clear inverse association between coffee consumption and risk of localized PCa, especially among overweight and obesemen.
Entities:
Keywords:
coffee; epidemiology; prospective cohort study; prostate cancer
Authors: Joshua Petimar; Kathryn M Wilson; Kana Wu; Molin Wang; Demetrius Albanes; Piet A van den Brandt; Michael B Cook; Graham G Giles; Edward L Giovannucci; Gary E Goodman; Phyllis J Goodman; Niclas Håkansson; Kathy Helzlsouer; Timothy J Key; Laurence N Kolonel; Linda M Liao; Satu Männistö; Marjorie L McCullough; Roger L Milne; Marian L Neuhouser; Yikyung Park; Elizabeth A Platz; Elio Riboli; Norie Sawada; Jeannette M Schenk; Shoichiro Tsugane; Bas Verhage; Ying Wang; Lynne R Wilkens; Alicja Wolk; Regina G Ziegler; Stephanie A Smith-Warner Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-04-26 Impact factor: 4.254
Authors: J Petimar; É O'Reilly; H-O Adami; P A van den Brandt; J Buring; D R English; D M Freedman; G G Giles; N Håkansson; T Kurth; S C Larsson; K Robien; L J Schouten; E Weiderpass; A Wolk; S A Smith-Warner Journal: Eur J Neurol Date: 2018-11-09 Impact factor: 6.089
Authors: Minh-Phuong Huynh-Le; Roshan Karunamuni; Chun Chieh Fan; Lui Asona; Wesley K Thompson; Maria Elena Martinez; Rosalind A Eeles; Zsofia Kote-Jarai; Kenneth R Muir; Artitaya Lophatananon; Johanna Schleutker; Nora Pashayan; Jyotsna Batra; Henrik Grönberg; David E Neal; Børge G Nordestgaard; Catherine M Tangen; Robert J MacInnis; Alicja Wolk; Demetrius Albanes; Christopher A Haiman; Ruth C Travis; William J Blot; Janet L Stanford; Lorelei A Mucci; Catharine M L West; Sune F Nielsen; Adam S Kibel; Olivier Cussenot; Sonja I Berndt; Stella Koutros; Karina Dalsgaard Sørensen; Cezary Cybulski; Eli Marie Grindedal; Florence Menegaux; Jong Y Park; Sue A Ingles; Christiane Maier; Robert J Hamilton; Barry S Rosenstein; Yong-Jie Lu; Stephen Watya; Ana Vega; Manolis Kogevinas; Fredrik Wiklund; Kathryn L Penney; Chad D Huff; Manuel R Teixeira; Luc Multigner; Robin J Leach; Hermann Brenner; Esther M John; Radka Kaneva; Christopher J Logothetis; Susan L Neuhausen; Kim De Ruyck; Piet Ost; Azad Razack; Lisa F Newcomb; Jay H Fowke; Marija Gamulin; Aswin Abraham; Frank Claessens; Jose Esteban Castelao; Paul A Townsend; Dana C Crawford; Gyorgy Petrovics; Ron H N van Schaik; Marie-Élise Parent; Jennifer J Hu; Wei Zheng; Ian G Mills; Ole A Andreassen; Anders M Dale; Tyler M Seibert Journal: Prostate Cancer Prostatic Dis Date: 2022-02-12 Impact factor: 5.455